Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego
Ubiquigent and Debiopharm have teamed up to support the development of Debiopharm’s ubiquitin-specific protease 1 (USP1) inhibitor programme, Debio 0432.
Ubiquigent and Debiopharm Enter Agreement to Support for Debio 0432
Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research
TransCode Therapeutics and Debiopharm Announce Collaboration
Genialis and Debiopharm Set Up Biomarker Discovery Collaboration
Debiopharm and ThinkingNodeLife.ai Forge a Strategic Partnership
Debiopharm Extends SunRock Biopharma Partnership for ADC
Debiopharm and Repare Therapeutics Partner to Explore PKMYT1 and WEE1
Debiopharm Innovation Fund Launches New Seed Funding Activity to Accelerate Digital Transformation of Cancer Care and Pharma R&D